Home › Complex Regional Pain Syndrome › NCT02502162

Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

Who can join

Ages 18 to 70 · All sexes

Inclusion Criteria:

* Upper and/or lower extremity CRPS
* On stable treatment for 1 month
* CRPS for at least 1 year
* Meet the Budapest criteria for CRPS at time of the study.

Exclusion Criteria:

* Any known allergy to naltrexone or naloxone
* Use of prescription opioid analgesics or illegal opioid use
* Current or planned pregnancy.

About the study

The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.

What is being tested

• LDN (drug)
• Placebo (drug)

Sponsor: Stanford University · Participants: 120 · Started: 2015-06

Contact the study team

• Birute Gedrimaite · Phone: (650) 497-0485

Official record on ClinicalTrials.gov — NCT02502162

Locations in the U.S.

Conditions

• Complex Regional Pain Syndrome

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.